RxDoctor Payments Data

Crystelle Canuto, NP

Family · Columbia, MONPI 1063076313

Payments from drug & device makers

$8,993in general payments, 2019–2025

Across 362 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$1K
  • EMD Serono, Inc.$493
  • Livanova USA, Inc.$399
  • SK Life Science, Inc.$396
  • Novartis$381
  • plus $4K from 46 others

What the payments were for

  • Travel & lodging$1,77020%
  • Food & beverage$7,06579%
  • Education$1582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,993 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$57,043
Medicare patients
269
Services billed
3,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NourianzIstradefylline17$49,662
Emgality PenGalcanezumab-Gnlm47$34,297
Nurtec OdtRimegepant Sulfate24$33,727
AptiomEslicarbazepine Acetate19$32,870
UbrelvyUbrogepant22$27,949
Ajovy AutoinjectorFremanezumab-Vfrm13$22,205
NeuproRotigotine15$22,096
XcopriCenobamate13$17,842
FycompaPerampanel12$14,645
Rasagiline Mesylate67$12,878
RytaryCarbidopa/Levodopa17$9,087
Carbidopa-LevodopaCarbidopa/Levodopa270$8,494
EliquisApixaban13$7,189
Memantine Hcl219$6,438
Entacapone11$4,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Nourianz$118$49,66217 claims
PfizerNurtec Odt, Eliquis$194$40,91637 claims
Sunovion Pharmaceuticals Inc.Aptiom$141$32,87019 claims
AbbVieUbrelvy$1,062$27,94922 claims
UCB, Inc.Neupro$221$22,09615 claims
SK Life Science, Inc.Xcopri$396$17,84213 claims
Eisai Inc.Fycompa$41$14,64512 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$64$11,51346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →